News
Buyout Bid Overshadows NxStage Medical's Losses
Dialysis patients know how inconvenient it can be to make time for their treatments, and NxStage Medical (NASDAQ: NXTM) has sought to make dialysis much less of a burden through its home dialysis
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
3 Stocks Hitting 52-Week Lows: Time to Go Bargain Shopping?
There's an old saying that a rising tide lifts all boats. That's true -- but only if the boats don't have holes in them. With the S&P 500 index hitting an all-time high recently, most stocks are
Why Teva Pharmaceutical Industries, Intrepid Potash, and Ensco Slumped Today
Monday was another good day for stocks, as major benchmarks continued their slow but steady ascent. Without much in the way of market-moving news on the geopolitical or macroeconomic fronts, investors
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
bluebird bio Pauses During 2017 Data Blitz
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and
Why NxStage Medical, Inc. Is Skyrocketing Today
Shares of NxStage Medical (NASDAQ: NXTM), a medical device maker focused on end-stage renal disease and acute kidney failure, jumped 28% as of 11:40 a.m. EDT on Monday.NxStage Medical reported its
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
These 3 Biotechs Just Crushed Analyst Expectations
Earnings season is under way, and biotech business appears to be booming. But it takes more than just a good quarter to know if a biotech is poised for sustainable, long-term growth. With many
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news
Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad Year
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One's Bill Mann consider how much worse Teva Pharmaceutical Industries (NYSE: TEVA) looks presently, after a second quarter
Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc
Investing in medical device companies can be ridiculously profitable.Since their respective IPOs, shares of Intuitive Surgical (NASDAQ: ISRG) -- maker of the daVinci robotic surgical system -- and
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
Tesla Speeds Ahead, While Teva Hits the Skids
On this Market Foolery podcast, host Chris Hill and Motley Fool One's Bill Mann discuss two very different companies with two wildly different places in the market today.As electric-car innovator
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings
Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two big-cap biotech stocks, and each recently reported second-quarter financial results that were better than
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a staple in the portfolios of conservative long-term investors and seniors alike.For decades, J&J, as the company is more commonly known, has
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very
Quintiles IMS Holdings Continues to Execute
Quintiles IMS Holdings (NYSE: Q), a leading service provider to the healthcare and life sciences industries, reported its second-quarter results on Aug. 3. While year-over-year comparisons continue to
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.MetricQ2 2017Continue
Why Teva Pharmaceutical Industries Stock Fell for a Second Straight Day
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down 9.8% as 1:15 p.m. EDT after dropping by an even greater amount yesterday following disappointing second-quarter results and lowered
BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter
BioMarin Pharmaceutical (NASDAQ: BMRN) turned in a second-quarter report on Wednesday that showed it continuing to grow sales of its current drugs, getting new drugs approved, and producing promising
Why AstraZeneca plc Stock Broke Down in July
Big Pharma stocks don't usually drop by double-digits over the course of a month, but that's exactly what happened to British pharma giant AstraZeneca plc (NYSE: AZN) in July. Due to the late-stage